Argenx tops STOXX on strong gMG drug Vyvgart sales momentum

argenx SE

31/07/2025 08:30

** Shares in pharma company argenx ARGX.BR soar more than 11% after what KBC sees as a "strong" Q2 earnings

** Vyvgart, argenx's drug for generalised myasthenia gravis (gMG), generates Q2 sales of $949 million, which, KBC says, beat market expectations by about 10%

** The product's FY revenue consensus currently stands at $3.59 bln, KBC adds, which is "well within reach"

** Van Lanschot Kepmen echoes comments of a "solid quarter" for the drug, whose sales it sees as key for the shares to perform

** "Further pipeline progress can polish the all-round investment case," Kempen adds pointing to a promising recent progress of ARGX-119 into phase 3 for congenital myasthenic syndromes (CMS)

** The stock tracks its biggest single-day jump since mid-March 2024 and sits on top of pan-European STOXX 600 index .STOXX

 (Reporting by Piotr Lipinski)

 ((piotr.lipinski@tr.com))